Your health isn’t about one test, one exam, or one doctor’s visit. Your health is the sum total of all that you do, all that you experience, all that you inherit, and all that makes you, you.
With that in mind, we created our most comprehensive offering yet. 23andMe+ Total Health™ is a longevity platform with the tools necessary to age to your fullest potential. With exome sequencing, blood biomarker analysis, Biological Age, and expert clinician oversight — Total Health helps you architect your healthiest life. It offers personalized, preventive care that is largely unavailable in today’s traditional healthcare system.
“Longevity isn’t about living more years,” said Noura Abul-Husn, MD, Ph.D. and Vice President of Genomic Health at 23andMe. “It’s about living more healthy years. And the key to doing that is within us.”
Actionable Exome Sequencing
Total Health begins with clinician-ordered exome sequencing* and interpretation of 100+ genes linked to more than 55 health conditions, including various types of cancer, cardiovascular diseases, metabolic, kidney, and neurological conditions. These include genes deemed the most ‘medically actionable’ by the American College of Medical Genetics and Genomics. The information from exome sequencing can be used for early detection or clinical interventions to help prevent or manage these conditions.
For most of 23andMe’s offerings, we use genotyping, a very efficient, fast, and accurate way to look at specific spots in the genome where differences influence health risks** and traits. In contrast, exome sequencing looks at the full sequence of sections of DNA. You can sequence a short piece, the entire genome, or parts of it, like the “exome.” The exome is the portion of the genome that provides the blueprint for protein creation and contains most of the known genetic variants that cause disease.
With exome sequencing, Total Health analyzes 200x more disease-causing variants than genotyping.**** These conditions are missed in traditional clinical settings and may be preventable with early detection.
Don’t Guess, Test with Biannual Blood Labs
Pairing genetic information with biannual blood testing gives Total Health members dynamic biomarker data to track changes over time. Without that kind of tracking, you’re often left guessing whether the actions you take have an impact. What’s more, with 70 percent of clinical decisions relying on blood tests and lab data, according to the Centers for Disease Control Division of Laboratory Systems, it’s more important than ever to get it right.
Total Health’s blood panels examine more than 55 different biomarkers. These panels offer insight into blood sugar and cholesterol changes and look at kidney, liver, and thyroid function. For example, Total Health members learn their lipoprotein(a) and apolipoprotein B (ApoB) levels, which are rarely tested cholesterol markers related to heart disease. The labs also look at such things as hemoglobin A1c (HbA1c), which is crucial in determining one’s risk of diabetes. Other biomarkers are analyzed to examine lipids, liver enzymes, electrolytes, and blood cells.
By including these tests twice yearly, Total Health members can track results and see leading indicators for cardiovascular disease, metabolic conditions, and more.
Biological Age: Age with Health
Your chronological or calendar age doesn’t necessarily reflect your body’s true health state, which is at the heart of Total Health’s Biological Age feature. A critical component in understanding longevity, Biological Age reveals your “true” age based on how your body functions.
Total Health members can use this feature to calculate their biological age using blood-based biomarkers. This feature reveals your age based on how your body functions, offering opportunities to take healthy actions. While you can’t change your birthdate, you can take steps to lower your biological age. Biannual blood tests, part of Total Health, help track that progress.
Total Health with a Clinician by Your Side
Genetics provides the foundation for Total Health, and blood biomarkers and Biological Age add dynamic data to gauge current health progress. To maximize the effectiveness of this sophisticated health data, clinicians trained in genetics-informed care guide members on their health journey.
Total Health clinicians create an actionable health plan based on each member’s unique results and deliver it via in-depth virtual consultation. These clinicians can also be reached at any time via direct messaging.
Total Health and Much More
Along with exome sequencing, blood biomarker analysis, Biological Age, and access to specially trained clinicians, Total Health members also have complete access to all health and ancestry reports, including 23andMe+ Premium’s advanced features and FDA-authorized health reports**.
This includes access to pharmacogenetics reports, which analyze how genetics may impact the processing of certain medications*****. In addition, Total Health members receive polygenic risk score reports***, which use proprietary statistical models developed by 23andMe scientists to calculate the likelihood of developing breast, prostate, or colorectal cancer and other conditions such as high blood pressure, asthma, and anxiety.
23 Chromosome Pairs, 55 Blood Biomarkers, 200x More Answers
In 2023, 23andMe launched Total Health as the first of its health memberships to provide comprehensive health analysis. This month, we’re launching a refreshed Total Health with full capabilities and an easy upgrade path for current U.S. customers tested on our V5 genotyping chip. Learn more about longevity with Total Health here.
* Exome Sequencing and blood testing services are available to eligible customers upon completion of the intake questionnaire, which must be reviewed, approved, and ordered by a third-party clinician. Exome Sequencing is analyzed by a CLIA—and CAP-accredited laboratory. Blood testing is completed by Quest Diagnostics. All telehealth services are provided under the Telehealth Terms and Consent to Telehealth.
** The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include reports that meet FDA requirements for genetic health risks and reports based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva to report and interpret genetic health risks and report carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/
*** The 23andMe PRS reports are based on a genetic model that includes data and insights from 23andMe consented research and incorporates thousands of genetic variants to describe if a person has a certain likelihood of developing a condition but does not describe a person’s overall likelihood. The PRS reports do not account for lifestyle or family history and have not been reviewed by the US Food and Drug Administration. The PRS reports are not intended to tell you anything about your current state of health or to be used to make medical decisions or determine any treatment.
Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit www.23andme.com/test-info.
****Our genotyping product detects 250 health-related variants in our Carrier Status and Genetic Health Risk reports. The Exome Sequencing reports detect 50,000+ hereditary disease-causing variants.
*****23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene, and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva to report and interpret information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with the metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy.
